On May 11, 2026, Catawba River Capital disclosed in a Securities and Exchange Commission (SEC) filing that it sold 199,018 shares of Cadre Holdings (NYSE:CDRE) in the first quarter, an estimated $7.95 million transaction based on quarterly average pricing. According to a filing published by the SEC on May 11, 2026, Catawba River Capital sold 199,018 shares of Cadre Holdings during the first quarte...
On May 11, 2026, Catawba River Capital disclosed in a Securities and Exchange Commission (SEC) filing that it sold 199,018 shares of Cadre Holdings (NYSE:CDRE) in the first quarter, an estimated $7.95 million transaction based on quarterly average pricing. According to a filing published by the SEC on May 11, 2026, Catawba River Capital sold 199,018 shares of Cadre Holdings during the first quarter. The estimated transaction value was $7.95 million, calculated using the average closing price for the period. The fund’s remaining stake at the end of the quarter stood at 260,318 shares, valued at $8.37 million. The net position value change, including price movement, was a decrease of $10.38 million. Cadre Holdings is a leading provider of protective equipment for law enforcement and first responders, leveraging a broad product portfolio and established brands to address critical safety needs. The company’s dual-segment model supports diversified revenue streams and positions it as a key supplier to both domestic and international government agencies. Scale, specialized expertise, and a strong reputation for reliability underpin its competitive advantage in the safety and defense industry. Continue reading
Alico press release ( ALCO ): Q2 GAAP EPS of $1.49 beats by $0.40 . Revenue of $5.34M (-70.3% Y/Y) beats by $2.89M . Fiscal Year 2026 Guidance The company expects to realize in fiscal year 2026 Adjusted EBITDA of approximately $14 million and end the fiscal year with cash of approximately $40 million and net debt of approximately $45 million, with only the minimum required balance of $2.5 million ...
Alico press release ( ALCO ): Q2 GAAP EPS of $1.49 beats by $0.40 . Revenue of $5.34M (-70.3% Y/Y) beats by $2.89M . Fiscal Year 2026 Guidance The company expects to realize in fiscal year 2026 Adjusted EBITDA of approximately $14 million and end the fiscal year with cash of approximately $40 million and net debt of approximately $45 million, with only the minimum required balance of $2.5 million on its revolving line of credit. This cash guidance reflects the deployment of $10.0 million for the stock repurchase program through April 2026. In the event that any additional capital is returned to shareholders through increased common dividends, special dividends, tender offers or open market share repurchases during the 2026 fiscal year, the Company’s cash balance could be further reduced and net debt could be correspondingly increased. More on Alico Seeking Alpha’s Quant Rating on Alico Historical earnings data for Alico Dividend scorecard for Alico Financial information for Alico
Natural Gas Services press release ( NGS ): Q1 GAAP EPS of $0.53 beats by $0.08 . Total revenue of $48.5M (+17.2% Y/Y) beats by $1.37M . Adjusted EBITDA increased 25.8% to $24.3 million for the three months ended March 31, 2026, from $19.3 million for the same period in 2025. Corporate Guidance — 2026 Outlook The Company now expects 2026 Adjusted EBITDA of $92.5 million to $97.5 million, compared ...
Natural Gas Services press release ( NGS ): Q1 GAAP EPS of $0.53 beats by $0.08 . Total revenue of $48.5M (+17.2% Y/Y) beats by $1.37M . Adjusted EBITDA increased 25.8% to $24.3 million for the three months ended March 31, 2026, from $19.3 million for the same period in 2025. Corporate Guidance — 2026 Outlook The Company now expects 2026 Adjusted EBITDA of $92.5 million to $97.5 million, compared to prior guidance of $90.5 to $95.5 million. The updated guidance reflects strong first quarter performance, high utilization, and contracted fleet expansion balanced with expectations for inflationary pressures in the remainder of 2026. Outlook FY 2026 Adjusted EBITDA $92.5 million - $97.5 million FY 2026 Growth Capital Expenditures $55.0 million - $70.0 million FY 2026 Maintenance Capital Expenditures $15.0 million - $18.0 million Click to enlarge More on Natural Gas Services Natural Gas Services: Due For A Valuation Re-Rating Natural Gas Services: Naturally Strong With Potential Growth Drivers To Support Valuation Natural Gas Services Group, Inc. (NGS) Q4 2025 Earnings Call Transcript NGS outlines $90.5M–$95.5M adjusted EBITDA guidance for 2026 as large horsepower fleet expansion continues Natural Gas Services GAAP EPS of $0.32 misses by $0.05, revenue of $44.3M beats by $0.5M
GoPro ( GPRO ) said on Monday its board authorized a formal review of strategic alternatives that could include a sale of the company or a merger. Shares of the company rose 3% in after-hours trading. "We are excited to work with our advisors to evaluate potential opportunities in various sectors to maximize shareholder value," said CEO Nicholas Woodman The company added that it recently received ...
GoPro ( GPRO ) said on Monday its board authorized a formal review of strategic alternatives that could include a sale of the company or a merger. Shares of the company rose 3% in after-hours trading. "We are excited to work with our advisors to evaluate potential opportunities in various sectors to maximize shareholder value," said CEO Nicholas Woodman The company added that it recently received several unsolicited strategic inquiries following its push into defense and aerospace markets. The review comes after GoPro engaged consulting firm Oliver Wyman in April to support expansion into defense-related applications. The CEO said the company plans to evaluate opportunities tied to its technology, intellectual property, manufacturing capabilities, and brand assets. GoPro said it has not set a timetable for the review process and cautioned there is no assurance any transaction will result. More on GoPro GoPro: Reiterating My Sell Rating On Weak Demand And Poor Fundamentals GoPro: Stronger Profit Execution Offset By Thin Liquidity And Storage Risks GoPro, Inc. (GPRO) Q4 2025 Earnings Call Transcript GoPro Non-GAAP EPS of -$0.35, revenue of $99.07M GoPro launches new MISSION camera series
AlTi Global press release ( ALTI ): Q1 Revenue of $73.1M (+26.0% Y/Y) beats by $9.3M . • Adjusted EBITDA of $15 million, increased 21% compared to Q1 25, largely driven by the higher management and incentive fees. More on AlTi Global AlTi Global, Inc. 2025 Q4 - Results - Earnings Call Presentation AlTi Global, Inc. (ALTI) Q4 2025 Earnings Call Transcript AlTi targets $20M in recurring annual gross...
AlTi Global press release ( ALTI ): Q1 Revenue of $73.1M (+26.0% Y/Y) beats by $9.3M . • Adjusted EBITDA of $15 million, increased 21% compared to Q1 25, largely driven by the higher management and incentive fees. More on AlTi Global AlTi Global, Inc. 2025 Q4 - Results - Earnings Call Presentation AlTi Global, Inc. (ALTI) Q4 2025 Earnings Call Transcript AlTi targets $20M in recurring annual gross savings by year-end 2026 as CEO transition and strategic review continue AlTi Global appoints Nancy Curtin as interim CEO Seeking Alpha’s Quant Rating on AlTi Global
Earnings Snapshot (Seeking Alpha) More on Quantum Computing D-Wave Quantum Vs. Quantum Computing: Early Revenue Premium Masks Long-Term Parity Quantum Computing: Rating Upgrade After Q4 Inflection Quarter More I Look At Quantum Computing, More I Like It: Upgrading To Buy Earnings week ahead: BABA, CSCO, PLUG, AMAT, JD, and more Quantum Computing Q1 2026 Earnings Preview
Earnings Snapshot (Seeking Alpha) More on Quantum Computing D-Wave Quantum Vs. Quantum Computing: Early Revenue Premium Masks Long-Term Parity Quantum Computing: Rating Upgrade After Q4 Inflection Quarter More I Look At Quantum Computing, More I Like It: Upgrading To Buy Earnings week ahead: BABA, CSCO, PLUG, AMAT, JD, and more Quantum Computing Q1 2026 Earnings Preview
Monty Rakusen/DigitalVision via Getty Images Boston Scientific Corporation ( BSX ) was founded in 1979 and is headquartered in Massachusetts. It specializes in medical devices sold to physicians and hospitals, principally dividing its business into two main segments : Cardiovascular and MedSurg. Within the former (representing approximately 2/3 of their revenue), they serve interventional cardiolo...
Monty Rakusen/DigitalVision via Getty Images Boston Scientific Corporation ( BSX ) was founded in 1979 and is headquartered in Massachusetts. It specializes in medical devices sold to physicians and hospitals, principally dividing its business into two main segments : Cardiovascular and MedSurg. Within the former (representing approximately 2/3 of their revenue), they serve interventional cardiology and vascular therapies, Watchman/cardiac rhythm management, electrophysiology, interventional oncology, and embolization. Their MedSurg segment (representing 1/3 of their revenue) includes devices serving endoscopy, urology, and neuromodulation. The company announced Q1 2026 earnings on April 22. BSX Q1 2026 earnings presentation Over the years, they have developed a host of transformative devices and therapies, providing solutions to save lives. They continue to work at the forefront of medical sciences and are considered one of the leading companies in this space. Over a 5-year period, BSX shares has underperformed the market, but only because the stock price has declined 50% from its all-time high in mid 2025. Seeking Alpha With this significant drawdown, investors will be interested to know whether – and crucially, when – a rebound might occur. What kind of growth can we expect in the company going forward? In this article, I’ll assess its business and broader industry, before considering various financial and valuation metrics to offer a risk/reward profile outlook. Business Prospects In the Q1 2026 results , Boston Scientific (hereafter: Boston) showed just 6% growth in MedSurg with its neuromodulation offerings representing the fastest growing (but also smallest) segment. With its cardiovascular segment, its Watchman system for treating non-valvular atrial fibrillation (AF) – an alternative to anticoagulant therapies (blood thinners) for patients with stroke risk – saw 19% y/y revenue growth. This and its electrophysiology (EP) segment represent the fastest-growin...
PagerDuty ( PD ) appointed John DiLullo as chief executive officer effective May 11, 2026. Jennifer Tejada stepped down as CEO and transitioned to executive chair of the board. Before joining PagerDuty, DiLullo served as CEO of Deepwatch and previously led LiveVox and Lastline. PagerDuty reaffirmed its Q1 FY2027 revenue guidance of $118M to $120M and full-year revenue guidance of $488.5M to $496.5...
PagerDuty ( PD ) appointed John DiLullo as chief executive officer effective May 11, 2026. Jennifer Tejada stepped down as CEO and transitioned to executive chair of the board. Before joining PagerDuty, DiLullo served as CEO of Deepwatch and previously led LiveVox and Lastline. PagerDuty reaffirmed its Q1 FY2027 revenue guidance of $118M to $120M and full-year revenue guidance of $488.5M to $496.5M. The company reaffirmed projected non-GAAP EPS of $0.23–$0.25 for Q1 FY2027 and $1.23–$1.28 for the full fiscal year. PagerDuty expects to report Q1 FY2027 financial results on May 28, 2026. More on PagerDuty The Bottom Fishing Club: PagerDuty - Time To Rebound? PagerDuty: A Clear 'Sell' As Churn Issue Worsens (Downgrade) PagerDuty's Weak Growth And Customer Churn Undermine Consumption Model Shift (Downgrade) PagerDuty gains amid activist investor speculation SA analyst upgrades/downgrades: MSFT, SPOT, ULTA, PD
DUBLIN, IRELAND, May 11, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2026 fourth quarter and full year ended March 31, 2026. Total revenue from continuing operations for the fourth quarter of fiscal 2026 increased 7% to $1.6 billion compared with $1.5 billion in the fourth quarter of fiscal 2025. Constant currency org...
DUBLIN, IRELAND, May 11, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2026 fourth quarter and full year ended March 31, 2026. Total revenue from continuing operations for the fourth quarter of fiscal 2026 increased 7% to $1.6 billion compared with $1.5 billion in the fourth quarter of fiscal 2025. Constant currency organic revenue growth from continuing operations grew 5% in the fourth quarter.
In the first full quarter since launch, 2,145 healthcare providers prescribed TONMYA ® , 3,588 patients initiated treatment, and ~5,400 prescriptions were filled
In the first full quarter since launch, 2,145 healthcare providers prescribed TONMYA ® , 3,588 patients initiated treatment, and ~5,400 prescriptions were filled
ATLANTA, May 11, 2026 (GLOBE NEWSWIRE) -- Bakkt, Inc. (“Bakkt,” “Company,” “we” or “us”) (NYSE: BKKT) announced its financial and operational results for the quarter ended March 31, 2026 and provided an update on certain business developments.
ATLANTA, May 11, 2026 (GLOBE NEWSWIRE) -- Bakkt, Inc. (“Bakkt,” “Company,” “we” or “us”) (NYSE: BKKT) announced its financial and operational results for the quarter ended March 31, 2026 and provided an update on certain business developments.
Ramaco press release ( METC ): Q1 GAAP EPS of -$0.15 beats by $0.06 . Revenue of $121.6M (-9.7% Y/Y) misses by $9.42M . The Company reiterates all previous key operational guidance across the board for full-year 2026. For the second quarter of 2026, we anticipate coal shipments of between 900,000 – 1,000,000 tons, with an ability to increase this figure depending on market conditions. We expect ca...
Ramaco press release ( METC ): Q1 GAAP EPS of -$0.15 beats by $0.06 . Revenue of $121.6M (-9.7% Y/Y) misses by $9.42M . The Company reiterates all previous key operational guidance across the board for full-year 2026. For the second quarter of 2026, we anticipate coal shipments of between 900,000 – 1,000,000 tons, with an ability to increase this figure depending on market conditions. We expect cash costs towards the higher end of the full-year range for the second quarter on the back of elevated fuel costs due to the Iranian conflict. More on Ramaco Ramaco Resources: Brook Mine Optionality Makes It A Viable Rare Earth Play Ramaco Resources CAL NT 29 -- 8.375% Carry, Short-Dated, Low Duration Ramaco Resources: Patience Needed For This Coal Producer With Rare Earth Option Ramaco Resources on the rise as Goldman upgrades after stock's YTD weakness Small-cap materials stocks ranked by quant ratings after earnings season
The Macerich Company ( NYSE: MAC ) on Monday said it launched an underwritten public offering of 16 million shares of common stock. The shopping mall operator said it expects to grant underwriters a 30-day option to purchase up to an additional 2.4 million shares. Macerich said it plans to use the net proceeds to repay borrowings under its revolving credit facility, which were primarily used to fu...
The Macerich Company ( NYSE: MAC ) on Monday said it launched an underwritten public offering of 16 million shares of common stock. The shopping mall operator said it expects to grant underwriters a 30-day option to purchase up to an additional 2.4 million shares. Macerich said it plans to use the net proceeds to repay borrowings under its revolving credit facility, which were primarily used to fund the acquisition of Annapolis Mall, and for general corporate purposes, including additional property acquisitions and leasing investments at Annapolis Mall. Source: Press Release More on Macerich The Macerich Company (MAC) Presents at Citi's Miami Global Property CEO Conference 2026 - Slideshow The Macerich Company (MAC) Presents at Citi's Miami Global Property CEO Conference 2026 Transcript Macerich targets 88%-89% physical permanent occupancy through Path Forward plan as it expects at least 3% 2026 go-forward NOI growth Macerich acquires Annapolis Mall for $272M
Life360 press release ( LIF ): Q1 GAAP EPS of $0.03 beats by $0.05 . Revenue of $143.12M (+38.1% Y/Y) beats by $5.84M . For FY’26, Life360 expects to deliver: MAU growth of 17% to 20%, weighted toward the second half of the year; Consolidated revenue of $650 million to $685 million (YoY growth of 33% to 40%), increased from the previous range of $640 million to $680 million comprised of: Subscript...
Life360 press release ( LIF ): Q1 GAAP EPS of $0.03 beats by $0.05 . Revenue of $143.12M (+38.1% Y/Y) beats by $5.84M . For FY’26, Life360 expects to deliver: MAU growth of 17% to 20%, weighted toward the second half of the year; Consolidated revenue of $650 million to $685 million (YoY growth of 33% to 40%), increased from the previous range of $640 million to $680 million comprised of: Subscription revenue of $470 million to $475 million increased from $460 million to $470 million; Hardware revenue of $40 million to $50 million (unchanged); Advertising revenue of $98 million to $115 million (unchanged); Other revenue of $42 million to $45 million (unchanged); Adjusted EBITDA of $130 million to $140 million, increased from the previous range of $128 million to $138 million, which represents a margin of approximately 20%. As previously disclosed, due to timing of investments to support our growth, and typical seasonality, we anticipate Adjusted EBITDA to be lightly weighted in the first half of 2026, and heavily weighted in the second half of 2026. Shares +7.5% AH. More on Life360 Life360: A Compelling Buy As Valuation Compresses And EBITDA Surges (Rating Upgrade) Life360, Inc. (LIF) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript Life360, Inc. (LIF) Q4 2025 Earnings Call Transcript Uber and Life360 to allow for greater platform integration Seeking Alpha’s Quant Rating on Life360
On May 1, 2026, Peng Lu, Chief Medical Officer of Pharvaris N.V. (NASDAQ:PHVS) , sold 14,166 common shares for approximately ~$427,000 through a scheduled option exercise and immediate sale, as disclosed in the SEC Form 4 filing . Transaction value based on SEC Form 4 weighted average purchase price ($30.17); post-transaction value based on May 1, 2026 market close ($29.44). *1-year price change c...
On May 1, 2026, Peng Lu, Chief Medical Officer of Pharvaris N.V. (NASDAQ:PHVS) , sold 14,166 common shares for approximately ~$427,000 through a scheduled option exercise and immediate sale, as disclosed in the SEC Form 4 filing . Transaction value based on SEC Form 4 weighted average purchase price ($30.17); post-transaction value based on May 1, 2026 market close ($29.44). *1-year price change calculated using May 1, 2026, as the reference date. Continue reading
WEBTOON Entertainment Inc. press release ( WBTN ): Q1 Non-GAAP EPS of $0.07 beats by $0.08 . Revenue of $320.9M (-1.5% Y/Y) misses by $10.71M . Net Loss was $8.8 million, compared to $22.0 million in the prior year, driven primarily by better gross profit. Adjusted EBITDA was $9.5 million, compared to $4.1 million in the prior year, due to effective cost controls. Adjusted EBITDA Margin was 3.0%,...
WEBTOON Entertainment Inc. press release ( WBTN ): Q1 Non-GAAP EPS of $0.07 beats by $0.08 . Revenue of $320.9M (-1.5% Y/Y) misses by $10.71M . Net Loss was $8.8 million, compared to $22.0 million in the prior year, driven primarily by better gross profit. Adjusted EBITDA was $9.5 million, compared to $4.1 million in the prior year, due to effective cost controls. Adjusted EBITDA Margin was 3.0%, compared to 1.3% in the prior year. Diluted loss per share was $0.07, compared to diluted loss per share of $0.17 in the prior year. More on WEBTOON Entertainment Inc. WEBTOON: Sell The Disney Hype (Double Rating Downgrade) WEBTOON Entertainment Inc. (WBTN) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript WEBTOON Entertainment Inc. (WBTN) Q4 2025 Earnings Call Transcript Webtoon targets 2026 double-digit revenue growth with Disney partnership and AI-driven user expansion WEBTOON Entertainment Inc. Non-GAAP EPS of $0.00 beats by $0.04, revenue of $330.7M misses by $6.49M
Hims & Hers Health Inc. reported a first-quarter loss and sales that missed Wall Street estimates amid increasing competition in the weight-loss drug market. Revenue was $608 million, the company said in a statement Monday, below the average analyst estimate of $617.5 million. The company reported a loss of 40 cents a share in the period, compared with profit of 20 cents a share a year ago. The re...
Hims & Hers Health Inc. reported a first-quarter loss and sales that missed Wall Street estimates amid increasing competition in the weight-loss drug market. Revenue was $608 million, the company said in a statement Monday, below the average analyst estimate of $617.5 million. The company reported a loss of 40 cents a share in the period, compared with profit of 20 cents a share a year ago. The results come as the company moves away from the copycat versions of weight-loss medications that helped fuel its growth, instead prioritizing partnerships with brand-name products. In an increasingly crowded market, Hims’ future rests on developing more of these branded partnerships. Hims shares fell more than 10% in after-hours trading. The stock had fallen 10% this year through Monday’s close.